Fulvio Mavilio
Directeur Technique/Scientifique/R&D chez ORCHARD THERAPEUTICS PLC
Profil
Fulvio Mavilio is currently a Member at the European Molecular Biology Organization, a Professor-Molecular Biology at the Università degli Studi di Modena e Reggio Emilia, a Senior Vice President-Translational Science at Astellas Gene Therapies, Inc., and the Chief Scientific Officer at Orchard Therapeutics Plc.
Previously, Dr. Mavilio worked as a Discovery Director at AGC Biologics SpA from 2002 to 2005.
He also served as the Director of the Centre for Regenerative Medicine at the Università degli Studi di Modena e Reggio Emilia from 2006 to 2011.
From 1995 to 2002, he was the Director at the San Raffaele-Telethon Institute for Gene Therapy.
Additionally, he held the position of Director at the American Society of Gene & Cell Therapy.
From 2012 to 2017, he worked as the Chief Scientific Officer at Genethon, and he was also the Chief Scientific Officer at Smart Immune SAS.
Dr. Mavilio obtained his doctorate degree from the Università degli Studi di Roma Tor Vergata in 1979.
He also completed his undergraduate degree at the same institution in 1976.
Postes actifs de Fulvio Mavilio
| Sociétés | Poste | Début |
|---|---|---|
| AUDENTES THERAPEUTICS, INC. | Corporate Officer/Principal | 18/07/2017 |
| ORCHARD THERAPEUTICS PLC | Directeur Technique/Scientifique/R&D | 01/01/2022 |
| European Molecular Biology Organization | Corporate Officer/Principal | - |
| Università degli Studi di Modena e Reggio Emilia | Corporate Officer/Principal | - |
Anciens postes connus de Fulvio Mavilio
| Sociétés | Poste | Fin |
|---|---|---|
Genethon
 Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Directeur Technique/Scientifique/R&D | 01/01/2017 |
| Università degli Studi di Modena e Reggio Emilia | Corporate Officer/Principal | 01/01/2011 |
| MOLMED S.P.A. | Corporate Officer/Principal | 01/01/2005 |
| San Raffaele-Telethon Institute for Gene Therapy | Directeur/Membre du Conseil | 01/01/2002 |
Smart Immune SAS
 Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017. | Directeur Technique/Scientifique/R&D | - |
Formation de Fulvio Mavilio
| Università degli Studi di Roma Tor Vergata | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
AGC Biologics SpA
 AGC Biologics SpA Pharmaceuticals: MajorHealth Technology AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy. | Health Technology |
| San Raffaele-Telethon Institute for Gene Therapy | |
| European Molecular Biology Organization | |
American Society of Gene & Cell Therapy
 American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay. | Commercial Services |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
Smart Immune SAS
Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017. | Health Technology |
